Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Rhea-AI Summary

Agenus (NASDAQ: AGEN) will announce its Q2 2021 financial results on August 9, 2021, before market open. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results and provide a corporate update. The call can be accessed via U.S. and international dial-in numbers, and a live webcast will be available on Agenus' website. Agenus specializes in immuno-oncology, focusing on therapies that engage the immune system to combat cancer.

Positive

• Agenus is preparing to report its second quarter results, indicating ongoing operations and engagement with investors.
• The conference call and webcast provide transparency and a direct line for investors to receive updates.

Negative

• None.

Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET

LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.

Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International).
Conference ID number: 3686849.

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gsbikqz2.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

When will Agenus report its second quarter 2021 financial results?

Agenus will report its second quarter 2021 financial results on August 9, 2021.

What time is the conference call for Agenus' Q2 2021 earnings?

The conference call for Agenus' Q2 2021 earnings is scheduled for 8:30 a.m. ET on August 9, 2021.

How can I access the Agenus Q2 2021 conference call?

You can access the Agenus Q2 2021 conference call using the dial-in numbers provided in the press release.

What is the focus of Agenus as a company?

Agenus is an immuno-oncology company focused on developing therapies that activate the immune system to fight cancer.